125 related articles for article (PubMed ID: 35637143)
1. Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection.
Yi CH; Bair MJ; Wang JH; Wong MW; Liu TT; Lei WY; Liang SW; Lin L; Hung JS; Huang JF; Hsu YC; Chen CL
J Microbiol Immunol Infect; 2022 Aug; 55(4):643-650. PubMed ID: 35637143
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
Fagundes RN; Ferreira LEVVC; Pace FHL
PLoS One; 2020; 15(8):e0237005. PubMed ID: 32813740
[TBL] [Abstract][Full Text] [Related]
3. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
Juanbeltz R; Martínez-Baz I; San Miguel R; Goñi-Esarte S; Cabasés JM; Castilla J
PLoS One; 2018; 13(10):e0205277. PubMed ID: 30300395
[TBL] [Abstract][Full Text] [Related]
4. Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Younossi ZM; Stepanova M; Reddy R; Manns MP; Bourliere M; Gordon SC; Schiff E; Tran T; Younossi I; Racila A
Liver Int; 2019 Jan; 39(1):54-59. PubMed ID: 29893462
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center.
Sung JC; Bosh C; Wyatt B; Miller M; Harty A; Del Bello D; Knight S; Dieterich DT; Perumalswami PV; Branch AD
J Viral Hepat; 2020 Apr; 27(4):350-359. PubMed ID: 31742821
[TBL] [Abstract][Full Text] [Related]
6. Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response.
Gormley MA; Akiyama MJ; Rennert L; Howard KA; Norton BL; Pericot-Valverde I; Muench S; Heo M; Litwin AH
Clin Infect Dis; 2022 May; 74(9):1586-1593. PubMed ID: 34331539
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.
Serper M; Evon DM; Amador J; Stewart PW; Sarkar S; Lok AS; Sterling RK; Reeve BB; Golin CE; Rajender Reddy K; Lim JK; Reau N; Nelson DR; Di Bisceglie AM; Fried MW
Liver Int; 2021 Apr; 41(4):692-704. PubMed ID: 33387381
[TBL] [Abstract][Full Text] [Related]
8. Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.
Younossi ZM; Stepanova M; Racila A; Afendy A; Lawitz EJ; Schwabe C; Ruane PJ; Lalezari J; Reddy KR; Jacobson IM; Muir AJ; Gaggar A; Myers RP; Younossi I; Nader F
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):468-476.e11. PubMed ID: 31376493
[TBL] [Abstract][Full Text] [Related]
9. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R).
Ohlendorf V; Schäfer A; Christensen S; Heyne R; Naumann U; Link R; Herold C; Schiffelholz W; Günther R; Cornberg M; Serfert Y; Maasoumy B; Wedemeyer H; Kraus MR
J Viral Hepat; 2021 Aug; 28(8):1206-1218. PubMed ID: 34003549
[TBL] [Abstract][Full Text] [Related]
10. Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
Younossi ZM; Racila A; Muir A; Bourliere M; Mangia A; Esteban R; Zeuzem S; Colombo M; Manns M; Papatheodoridis GV; Buti M; Chokkalingam A; Gaggar A; Nader F; Younossi I; Henry L; Stepanova M
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):438-446. PubMed ID: 33493697
[TBL] [Abstract][Full Text] [Related]
11. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study.
Kaur H; Dhiman RK; Kulkarni AV; Premkumar M; Singh V; Duseja AK; Grover S; Grover GS; Roy A; Verma N; De A; Taneja S; Mehtani R; Mishra S; Kaur H
J Viral Hepat; 2022 May; 29(5):395-406. PubMed ID: 35266624
[TBL] [Abstract][Full Text] [Related]
12. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.
Nardelli S; Riggio O; Rosati D; Gioia S; Farcomeni A; Ridola L
World J Gastroenterol; 2019 Dec; 25(48):6928-6938. PubMed ID: 31908396
[TBL] [Abstract][Full Text] [Related]
15. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
[TBL] [Abstract][Full Text] [Related]
18. Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C.
de Avila L; Weinstein AA; Estep JM; Curry MP; Golabi P; Escheik C; Birerdinc A; Stepanova M; Gerber L; Younossi ZM
Liver Int; 2019 Sep; 39(9):1631-1640. PubMed ID: 30959554
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
[TBL] [Abstract][Full Text] [Related]
20. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
